iShares Core S&P 500 ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares Core S&P 500 ETF trades at $782.1 (market cap $897.20B), while Roivant Sciences Ltd. Common Shares trades at $35.07 (market cap $24.72B). The key difference: iShares Core S&P 500 ETF is far larger — about 36.3× Roivant Sciences Ltd. Common Shares's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| IVV | ROIV | |
|---|---|---|
Market Cap | $897.20B | $24.72B |
Volume | 4,580,672 | 6,279,442 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $41.81 |
52-Week Low | $634.93 | $16.04 |
Typical Hold Time | 46 Days | 1 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $779.68, down 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights mixed S&P 500 valuation signals, with earnings growth expected to slow in 2027 but historical seasonal patterns suggesting potential upside. The ETF's fundamentals reflect the index's aggregate metrics, with no company-specific financials reported.
Outlook remains cautiously optimistic given the bullish technical bias and index-level support, though risks include concentration in top holdings and macroeconomic headwinds. Investors gain diversified exposure to large-cap U.S. equities, but should monitor earnings trends and interest rate sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →